Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

Unity Biotechnology

Status and phase

Completed

Phase 2

Conditions

Neovascular Age-related Macular Degeneration

Treatments

Drug: UBX1325 injection 50 μL

Drug: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Study type

Interventional

Funder types

Industry

Identifiers

NCT05275205

UBX1325-03

Details and patient eligibility

About

This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.

Full description

This is a Phase 2 study. During Screening, every patient will receive a run-in injection of aflibercept. On Day 1, patients will be randomized to either the UBX1325 arm or the aflibercept arm. Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28; and sham procedure on Weeks 8, 16, 24, 32, and 40. Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28.

Enrollment

51 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients aged ≥50 years.
Active CNV associated with age-related macular degeneration as evidenced on FA and SD-OCT with presence of intraretinal or subretinal fluid at Screening and Day 1
BCVA in the study eye (most affected) of 70 to 20 ETDRS letters (equivalent to 20/40 to 20/400 on the Snellen chart) at Screening.
Patients who have the capacity to give informed consent and who are willing and able to comply with all study-related procedures and assessments.

Exclusion criteria

Concurrent disease in the study eye or structural damage, other than wet AMD, that could compromise BCVA, prevent BCVA improvement, require medical or surgical intervention during the study period, confound interpretation of the results, or interfere with assessment of toxicity or CFP in the study eye.
Any ocular/intraocular/periocular infection or inflammation in either eye in the past 12 weeks prior to screening
Subretinal hemorrhage with bleeding area of 4 or greater disc area in the study eye
History of vitreous hemorrhage in the study eye within 2 months prior to Screening
Any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation or prevent the patient from fully participating in all aspects of the study
Significant media opacities, including cataract, which might interfere with VA, assessment of toxicity, or fundus imaging